Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Palatin Technologies Inc (PTN)
NYSE MKT:PTN
Palatin Technologies (PTN) Stock Price & Analysis
2,720 Followers
PTN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.43 - $5.65
Previous Close$1.89
Volume180.64K
Average Volume (3M)711.19K
Market Cap
$30.50M
Enterprise Value$31.43M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$934.33K
Price to Earnings (P/E)-0.7
Beta1.56
Next Earnings
May 14, 2024EPS Estimate
-$0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.58
Shares Outstanding16,136,640
10 Day Avg. Volume1,559,809
30 Day Avg. Volume711,189
Standard Deviation0.25
R-Squared0.04
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)-2.65
Price to Sales (P/S)11.65
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.52
Enterprise Value/Gross Profit6.48
Enterprise Value/Ebitda-1.06
Forecast
1Y Price Target
$9.33Price Target Upside393.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Palatin Technologies News
Bulls Say, Bears Say
Bulls Say
Drug EfficacyPalatin's PL9643 showed statistical superiority to placebo in Phase 2 trials for dry eye disease, demonstrating early effectiveness.
Regulatory MilestonesPalatin plans to meet with the FDA to discuss a regulatory approval path, with NDA submission targeted for the second half of the next year.
Safety ProfilePL9643 was safe and well-tolerated with fewer incidence of adverse events or discontinuations vs. placebo.
Bears Say
Clinical Trial ResultsPhase 3 MELODY-1 study in dry eye for PL9643 did not achieve statistical significance in the ITT analysis.
Financial PerformancePalatin's recent earnings report showed a wider loss per share than expected, which included a significant noncash charge.
Regulatory ChallengesThe FDA has made it clear significant improvements to both signs and symptoms in pivotal studies are necessary for approval consideration.
---
Ownership Overview
75.05% Insiders
4.05% Mutual Funds
3.69% Other Institutional Investors
17.21% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
PTN FAQ
What was Palatin Technologies Inc’s price range in the past 12 months?
Palatin Technologies Inc lowest stock price was $1.43 and its highest was $5.65 in the past 12 months.
What is Palatin Technologies Inc’s market cap?
Currently, no data Available
When is Palatin Technologies Inc’s upcoming earnings report date?
Palatin Technologies Inc’s upcoming earnings report date is May 14, 2024 which is in 25 days.
How were Palatin Technologies Inc’s earnings last quarter?
Palatin Technologies Inc released its earnings results on Feb 15, 2024. The company reported -$0.56 earnings per share for the quarter, missing the consensus estimate of -$0.203 by -$0.357.
Is Palatin Technologies Inc overvalued?
According to Wall Street analysts Palatin Technologies Inc’s price is currently Undervalued.
Does Palatin Technologies Inc pay dividends?
Palatin Technologies Inc does not currently pay dividends.
What is Palatin Technologies Inc’s EPS estimate?
Palatin Technologies Inc’s EPS estimate is -$0.45.
How many shares outstanding does Palatin Technologies Inc have?
Palatin Technologies Inc has 16,136,640 shares outstanding.
What happened to Palatin Technologies Inc’s price movement after its last earnings report?
Palatin Technologies Inc reported an EPS of -$0.56 in its last earnings report, missing expectations of -$0.203. Following the earnings report the stock price went down -23.913%.
Which hedge fund is a major shareholder of Palatin Technologies Inc?
Among the largest hedge funds holding Palatin Technologies Inc’s share is Fortress Investment Group LLC. It holds Palatin Technologies Inc’s shares valued at 1K.
---
Palatin Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.33 (393.65% Upside)
$9.33 (393.65% Upside)
Blogger Sentiment
Bullish
PTN Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth $10.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.30%
12-Months-Change
Fundamentals
Return on Equity
-1274.20%
Trailing 12-Months
Asset Growth
-57.61%
Trailing 12-Months
Company Description
Palatin Technologies Inc
Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, a peptide melanocortin receptor 4 agonist for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.
---
PTN Earnings Call
Q2 2024
0:00 / 0:00
---
PTN Stock 12 Months Forecast
Average Price Target
$9.33
▲(393.65% Upside)
Technical Analysis
Eagle Pharmaceuticals
―
Karyopharm Therapeutics
―
Accelerate Diagnostics
―
Enanta Pharmaceuticals
―
Best Analysts Covering PTN
1 Year
1 Year Success Rate
6/23 ratings generated profit
1 Year Average Return
-27.64%
reiterated a buy rating 2 months ago
Copying Michael Higgins's trades and holding each position for 1 Year would result in 26.09% of your transactions generating a profit, with an average return of -27.64% per trade.
---